IGSF1 Protein, Human (Cell-Free, His)

The IGSF1 protein acts as a coreceptor in inhibin signaling and is able to critically antagonize activin A signaling regardless of the presence of inhibin B. It plays a key role in the specific antagonism of inhibin B to activin-stimulated transcription and interacts with INHA. IGSF1 Protein, Human (Cell-Free, His) is the recombinant human-derived IGSF1 protein, expressed by E. coli Cell-free , with N-10*His labeled tag. The total length of IGSF1 Protein, Human (Cell-Free, His) is 1336 a.a., with molecular weight of 151.8 kDa.

IGSF1 protein serves as a coreceptor in inhibin signaling, although it does not appear to function as a high-affinity inhibin receptor. It plays a crucial role in antagonizing activin A signaling, whether inhibin B is present or not. The protein is essential for mediating a specific antagonistic effect of inhibin B on activin-stimulated transcription, and it interacts with INHA. While a standard receptor binding assay indicated no interaction with INHA in one study, IGSF1 is known to interact with ACVR1B, and this interaction seems to be ligand-dependent, being diminished by inhibin B and activin A. Furthermore, IGSF1 interacts with ACVR2A, ACVR2B, ACVRL1, BMPR1B, and HECTD1, revealing its involvement in a complex network of protein interactions critical for modulating inhibin and activin signaling pathways.

Human

E. coli Cell-free

N-10*His

Q8N6C5 (M1-I1336)

3547

MTLDRPGEGATMLKTFTVLLFCIRMSLGMTSIVMDPQPELWIESNYPQAPWENITLWCRSPSRISSKFLLLKDKTQMTWIRPSHKTFQVSFLIGALTESNAGLYRCCYWKETGWSKPSKVLELEAPGQLPKPIFWIQAETPALPGCNVNILCHGWLQDLVFMLFKEGYAEPVDYQVPTGTMAIFSIDNLTPEDEGVYICRTHIQMLPTLWSEPSNPLKLVVAGLYPKPTLTAHPGPIMAPGESLNLRCQGPIYGMTFALMRVEDLEKSFYHKKTIKNEANFFFQSLKIQDTGHYLCFYYDASYRGSLLSDVLKIWVTDTFPKTWLLARPSAVVQMGQNVSLRCRGPVDGVGLALYKKGEDKPLQFLDATSIDDNTSFFLNNVTYSDTGIYSCHYLLTWKTSIRMPSHNTVELMVVDKPPKPSLSAWPSTVFKLGKAITLQCRVSHPVLEFSLEWEERETFQKFSVNGDFIISNVDGKGTGTYSCSYRVETHPNIWSHRSEPLKLMGPAGYLTWNYVLNEAIRLSLIMQLVALLLVVLWIRWKCRRLRIREAWLLGTAQGVTMLFIVTALLCCGLCNGVLIEETEIVMPTPKPELWAETNFPLAPWKNLTLWCRSPSGSTKEFVLLKDGTGWIATRPASEQVRAAFPLGALTQSHTGSYHCHSWEEMAVSEPSEALELVGTDILPKPVISASPTIRGQELQLRCKGWLAGMGFALYKEGEQEPVQQLGAVGREAFFTIQRMEDKDEGNYSCRTHTEKRPFKWSEPSEPLELVIKEMYPKPFFKTWASPVVTPGARVTFNCSTPHQHMSFILYKDGSEIASSDRSWASPGASAAHFLIISVGIGDGGNYSCRYYDFSIWSEPSDPVELVVTEFYPKPTLLAQPGPVVFPGKSVILRCQGTFQGMRFALLQEGAHVPLQFRSVSGNSADFLLHTVGAEDSGNYSCIYYETTMSNRGSYLSMPLMIWVTDTFPKPWLFAEPSSVVPMGQNVTLWCRGPVHGVGYILHKEGEATSMQLWGSTSNDGAFPITNISGTSMGRYSCCYHPDWTSSIKIQPSNTLELLVTGLLPKPSLLAQPGPMVAPGENMTLQCQGELPDSTFVLLKEGAQEPLEQQRPSGYRADFWMPAVRGEDSGIYSCVYYLDSTPFAASNHSDSLEIWVTDKPPKPSLSAWPSTMFKLGKDITLQCRGPLPGVEFVLEHDGEEAPQQFSEDGDFVINNVEGKGIGNYSCSYRLQAYPDIWSEPSDPLELVGAAGPVAQECTVGNIVRSSLIVVVVVALGVVLAIEWKKWPRLRTRGSETDGRDQTIALEECNQEGEPGTPANSPSSTSQRISVELPVPI

151.8 kDa

Greater than 90% as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.